Study of letermovir in people with severe kidney disease
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests how a single dose of an antiviral medicine called letermovir behaves in people with severe kidney disease, with or without regular haemodialysis. It aims to find the right dose for this population to prevent or treat infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have severe kidney disease, meaning your kidney function is very low (eGFR under 15).
- You may or may not be on regular haemodialysis (a treatment that cleans your blood).
- You must be willing to take a single 480 mg dose of the study drug.
- You must be able to give informed consent and have a small tube (cannula) placed for blood draws.
- You must not be taking certain medicines like statins (for cholesterol) or proton pump inhibitors (for stomach acid) unless they can be safely stopped temporarily.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral antiviral medication called letermovir to see if it safely prevents CMV (a common virus) in children who have recently had a kidney transplant. It's for children ages typically 4 weeks to about a year post-transplant, with stable kidney function and no current CMV infection.
This study compares two medications, letermovir and valganciclovir, to see which works better at preventing CMV infection in people who have received a kidney transplant and have previously been exposed to the virus. Taking part may help reduce the risk of a serious infection after transplant.
This trial studies whether letermovir can help prevent CMV (a common virus after transplant) from coming back after you’ve already been treated. If you qualify, you may be offered letermovir as “secondary prevention” and followed for about 6 months.
This trial tests if the drug letermovir can prevent a common virus (CMV) in children who have certain blood disorders and are getting a stem cell transplant. It aims to keep you safer during recovery.
This study tests whether a drug called letermovir can help keep the immune system calm and healthy in people over 50 with well-controlled HIV. It might reduce immune overactivation that can lead to other health problems.
This trial tests a combination of two antiviral drugs (letermovir and valganciclovir) to treat CMV infections in kidney transplant recipients. It aims to find a safer, more effective treatment option for people with active CMV after transplant.
Hear when a new End-Stage Kidney Disease (ESKD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.